Related Experiment Video
Updated: Jun 16, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Broad-spectrum anti-cancer activity of fused human arginase variants
Yenisetti Rajendra Prasad1, J Anakha1, Snehal Sainath Jawalekar1
1Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, Mohali, S.A.S. Nagar, 160062, Punjab, India.
Abstract:
The rapid increase in cancer cases worldwide necessitates the development of novel therapeutic approaches. Therapies targeting cancer's altered metabolism, especially those that deplete critical amino acids, have emerged as promising ones, some of which are already being used in clinical practice and many others are under development. This study reports the anti-cancer activity of two novel fused human arginase I (FHA) variants, FHA-3 and FHA-12, assessed using the NCI-60 human tumor cell line panel. Both variants have demonstrated a range of potencies in a single-dose assay (10 µM), but FHA-3 was found to be more potent with significant growth inhibition in most tested cell lines. To calculate 50% growth inhibition (GI50), FHA-3 was further evaluated in a five-dose assay, where notable anti-cancer activity was observed across the nine cancer types of the NCI-60 panel. Our results demonstrated the broad-spectrum anti-cancer activity of novel FHA variants, with FHA-3 being the most potent. Further studies elucidating its efficacy in animal models will help explore its therapeutic potential.
Insights
Novel fused human arginase I (FHA) variants show potent anti-cancer activity. FHA-3 demonstrated significant broad-spectrum tumor cell growth inhibition, indicating therapeutic potential.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Rising global cancer incidence demands innovative therapies.
- Targeting cancer's altered metabolism, including amino acid depletion, is a promising strategy.
- Fused human arginase I (FHA) variants are under investigation for anti-cancer applications.
Purpose of the Study:
- To evaluate the anti-cancer activity of two novel FHA variants, FHA-3 and FHA-12.
- To assess the potency and spectrum of activity against the NCI-60 human tumor cell line panel.
Main Methods:
- Screening of FHA-3 and FHA-12 using the NCI-60 human tumor cell line panel at a single dose (10 µM).
- Detailed dose-response evaluation of FHA-3 to determine 50% growth inhibition (GI50) values.
- Analysis of anti-cancer activity across nine different cancer types within the NCI-60 panel.
Main Results:
- Both FHA-3 and FHA-12 exhibited anti-cancer activity.
- FHA-3 displayed greater potency and significant growth inhibition across most tested cell lines.
- FHA-3 showed notable anti-cancer activity across all nine cancer types in the NCI-60 panel.
Conclusions:
- Novel FHA variants possess broad-spectrum anti-cancer properties.
- FHA-3 is a highly potent variant with significant therapeutic potential.
- Further investigation in preclinical animal models is warranted to explore FHA-3's therapeutic efficacy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...